1. Does H. pylori influence the number of relapses of ulcerative colitis? M. Tzouvala, M. Mylonaki, K. Triantafyllou, E. Tsironi, E. Varvate-Koutsoukou, G. Varvayiannis, C. Nicolopoulou, , D.G. Karamanolis. Digestion 1998; 59(suppl 3): 151: FoLM1352.
2. Predictive factors of post-treatment diagnostic accuracy of CLO-test in duodenal ulcer patients. K. Triantafyllou, Κ. Patikos, G. V. Papatheodoridis, M. Mylonaki, D. Zisis, V. Xourgias, D.G. Karamanolis. Digestion 1998; 59(suppl 3): 424: ExhB3181
3. Inflammatory Bowel Disease haunted by Cytomegalovirus infection. Κ. Patikos, M. Tzouvala, M. Mylonaki, Ch. Poulopoulou, K. Triantafyllou, V. Xourgias, D.G. Karamanolis. Gut 1999; 45(suppl V): P 1052
4. bcl-2, p53 and mdm2 protein expression in gastritis, dysplasia and gastric adenocarcinoma. K. Triantafyllou, M. Tzouvala, N. Kapranos, G. V. 35 Papathodoridis, A. Zizi, M. Mylonaki, D.G. Karamanolis. Gastroenterology 1999;116(4): G1941
5. Should colonoscopy be performed in all patients with non – advanced rectosigmoid adenomas? Κ. Patikos, M. Mylonaki, E. Tsironi, M. Michael, D. Zisis, D.G. Karamanolis. Annals of Gastroenterology 2000; 13(suppl 1): 16(p.130)
6. How often an advanced neoplasia exists in the proximal colon without an index polyp in the rectosigmoid? Κ. Patikos, M. Mylonaki, E. Tsironi, M. Tzouvala, K. Triantafyllou, V. Xourgias, D.G. Karamanolis. Annals of Gastroenterology 2000; 13(suppl 1): 70 (p. 157)
7. Does gastritis after H. Pylori eradication in patients with duodenal ulcer correlate with dyspeptic symptoms? K. Patikos, K. Triantafyllou, M.Tzouvala, M. Mylonaki, E. Tsironi, B. Xourgias, D.G. Karamanolis. Gut 2000; 47(suppl 3): A122.
8. Ιs there a relationship between H. Pylori and bleeding in NSAIDS user patients, with peptic ulcer? M.Tzouvala, K. Patikos, M. Mylonaki, E. Tsironi, B. Xourgias, D.G. Karamanolis. Gut 2000; 47(suppl 3): A86
9. Οbjective measures using image analysis in bleeding peptic ulcers. B. Xourgias, K. Patikos, E. Tsironi, M. Mylonaki, G. Giogas, D.G. Karamanolis . Gut 2000; 47(suppl 3): E28.
10. Does cure of the H. Pylori infection induce gastroesophageal reflux symptoms in patients with duodenal ulcer? B. Xourgias, K. Triantafyllou, M. Mylonaki, G. Katsoras, D.G. Karamanolis. Gastroenterology 2000; 118(suppl 2): 6048.
11. Adherent microbial populations in inflammatory bowel disease. N. B Rayment, M. Mylonaki, B.N Hudspith, K. Bruce, D. S Rampton, J. Brostoff Immunology 2001; 104(suppl 1):OP177
12. Prevalence of usage and tolerance of oral iron therapy in inflammatory bowel disease: are we using it appropriately and could we do better? A D. De Silva, M. Mylonaki, D S. Rampton. Gut 2001; 48 (suppl 1): A88.
13. Efficacy and usage of oral iron therapy in Inflammatory Bowel Disease. A D. De Silva, M. Mylonaki, D S. Rampton. Gastroenterology 2001; 120(suppl 1) : 1393
14. Reduced Bifidobacteria and increased E.coli in rectal mucosa – associated flora in active inflammatory bowel disease. N. Rayment, M. Mylonaki, B. 36 Hudspith, J. Brostof, D. Rampton. Gut 2002; 50 (suppl II): A29. Cited: 1.
15. ASCA and ANCA in the diagnosis of bowel disease and other diarrhoeal illnesses. M. Buckland, M. Mylonaki, D. S. Rampton, H. J. Longhurst. Gut 2002; 50 (suppl II): A67
16. Clinical results of wireless capsule endoscopy. Mylonaki M, Fritscher – Ravens A, Swain P. Gut 2002; 50 (suppl II): A17
17. Clinical studies of wireless capsule colonoscopy. Mylonaki M, Fritscher – Ravens A, Lewkowicz S, Swain P. Gut 2002; 50 (suppl II): A42
18. Increasing risk of Clostridium Difficile infection in patients presenting with relapse of inflammatory bowel disease. M. Mylonaki, F. Johnson, L. Langmead, D. Rampton. Gastroenterology 2002; 122 (suppl 1): W1307
19. ASCA and ANCA in the diagnosis of Inflammatory Bowel Disease and other diarrhoeal illnesses. M. Buckland, M. Mylonaki, D. S. Rampton, H. J. Longhurst. Gastroenterology 2002; 122 (suppl 1): S1183
20. ANCA/ASCA profile in the prediction of clinical phenotype in Crohn’s disease. M. Mylonaki, M. Buckland, H. Longhurst, A.D. de Silva, A. B. Ballinger, D. Rampton. Gastroenterology 2002; 122 (suppl 1): S1185
21. Clinical results of wireless capsule endoscopy. M. Mylonaki, A. Fritscher – Ravens, P. Swain . Gastrointestinal Endoscopy 2002; 55 (5): M2026
22. The effects of stress on gastrointestinal physiology using wireless capsule endoscopy observation. Α. Fritscher – Ravens, M. Mylonaki, P. Swain. Gastrointestinal Endoscopy 2002; 55 (5): M1968. Cited: 1.
23. Invasive microbial populations in inflammatory bowel disease. G. Shah, N. B. Rayment, M. Mylonaki, B. N. Hudspith, D. S. Rampton, J. Brostoff. Immunology 2002; 107(suppl 1):OP148.
24. Co-localisation of E.coli with macrophages in lamina propria in patients with active inflammatory bowel disease (IBD). N. Rayment, M. Mylonaki, D. Rampton, B. Hudspith, J. Brostoff. Gut 2003; 52: Page A13. Cited: 1.
25. Co-localisation of E.coli with macrophages in lamina propria in patients with active inflammatory bowel disease (IBD). N. Rayment, M. Mylonaki, D. Rampton, B. Hudspith, J. Brostoff. Αliment Pharmacol Ther 2003.
26. Risk of cervical intraepithelial neoplasia is not increased in patients on thiopurines for inflammatory bowel disease (IBD). M. Mylonaki, U. Menon, I. Jacobs, A. Ballinger, D. Rampton. Aliment Pharmacol Ther 2003. 37
27. ANCA AND ASCA profile in Bangladeshi patients with inflammatory bowel disease. E. Tsironi, M. Mylonaki, M. Buckland, H. Longhurst, D. Rampton. 3 rd International Inflammatory Bowel Disease Meeting, Chester, 9-11/2/2003. Accepted as a poster. Aliment Pharmacol Ther 2003.
28. Development and testing of an electrically propelled capsule endoscope in man. Fritcher-Ravens A, Burke P, Mills T, Mosse CA, Mylonaki M, Swain CP. Disease Week meetings, 17-22/5/2003, Orlando, Florida. (486, A-100) Gastrointestinal Endoscopy 2003. Cited: 4.
29. A study to access the diagnostic yield in small bowel disease in paediatric patients. Furman MA, Mylonaki M, Fritcher-Ravens A et al. Wireless capsule endoscopy in children: Digestive Disease Week meetings, 17-22/5/2003, Orlando, Florida. (565, A-115) Gastrointestinal Endoscopy 2003. Cited: 9
30. Profiling the bacterial community associated with the rectal mucosa in inflammatory bowel disease (IBD) using 16S rDNA denaturing gradient gel electrophoresis.Green G, Mylonaki M, Rampton D, et al. Digestive Disease Week meetings, 17-22/5/2003, Orlando, Florida. (T1067, A-670.) Gastroenterology 2003; 124 (4): Page A478.
31. Co- localisation of E. coli with macrophages in lamina propria in patients with active inflammatory bowel disease (IBD).Rayment N, Mylonaki M, Rampton D, et al. Digestive Disease Week meetings, 17-22/5/2003, Orlando, Florida (T1076, A-672). Gastroenterology 2003; 124 (4): A 479.
32. Experimental and clinical studies of wireless capsule colonoscopy. Swain P, Fritscher-Ravens A, Mylonaki M. Disease Week meetings, 15-20/5/2004, New Orleans. (464, A-96) Gastrointestinal Endoscopy 2004; 59 (5): Page P176. Cited: 3.
33. The assessment of wireless capsule endoscopy in paediatrics. Furman MA, Mylonaki M, Heuschkel R et al. Digestive Disease Week meetings, 1520/5/2004, New Orleans. (M1820, A-546) Gastrointestinal Endoscopy 2004; 59 (5): Page P 176.
34. Molecular characterisation of the Bacteria adherent to human colorectal mucosa. Green G, Brostoff J, Hudspith B, Michael M, Rayment N, Mylonaki M, Sanderson J, Staines N, Rampton D, Bruce K. Digestive Disease Week meetings, 14-19/5/2005, Chicago IL. (S1332, A-195) Gastroenterology 2005. 38
35. Early gastric cancer, atrophic gastritis and autoimmune hepatitis in the same patient: a very rare combination. M Mylonaki, M Sklavena, Α. Μastrangelis, F.Georgopoulos, A Parasi, G Drakoulis, G Peros, P Cheracakis, JK Triantafilli dis ακάκης. Digestive Oncology 2007.
36. Co-localisation of toll-like receptors with signalling molecules IRAk and NFkβ in colonic biopsies of patients with inflammatory bowel disease.De Costa A, Rayment N, Mylonaki M, Petrovska L, Hudspith B, Brostof J, Nunes C, Parkes G, Sanderson JD, Rampton DS. Gut 2006; 55 (S11): 291
37. Increased expression of TLRs’ is associated with an upregulation of signalling molecules IRAK-1 and NFkB in colonic biopsies of patients with inflammatory bowel disease. De Costa A, Rayment N, Mylonaki M, et al. Gastroenterology 2006 : M 17168
38. Infections from viruses, mivrobes and parasites in patients with inflammatory bowel disease: A 15 years experience.JK Triantafillidis, P Cheracakis, M Mylonaki, F Georgopoulos, A Stamataki, G Peros. Journal of Crohn’s and Colitis 2008; 2 (1): 45-46.
39. Epstein-Barr infection of the colon in a patient with severe first attack of ulcerative colitis.P. Cheracakis, Evangelia Dimitroulia, Aikaterini Triantafillidiss, G. Malgarinos, Chrissa Malli, J. Fouskas, V. Panteris, Maria Mylonaki, F. Georgopoulos, J.K. Triantafillidis. Hepatogastroenterology Supplement I 2008;55:A154 (P109)
40. Efficacy and safety of long-term infliximab administration in a Greek hospital setting. J.K. Triantafillidis, G. Malgarinos, Chrissa Malli, J. Fouskas, Maria Mylonaki, F. Georgopoulos, V. Panteris, P. Cheracakis, G. Peros Hepatogastroenterology Supplement I 2008;55:A305 (P478)
41. Intraabdominal abscesses in patients with Crohn’s disease: clinical data and therapeutic manipulations in 17 cases F. Georgopoulos, J. Fouskas, G. Malgarinos, Chrissa Malli, V. Panteris, Maria Mylonaki, P. Cheracakis, G. Peros, J.K. Triantafillidis. Hepatogastroenterology Supplement I 2008;55:A306 (P479.
